Predictive value of the modified Glasgow Prognostic Score for the therapeutic effects of molecular-targeted drugs on advanced renal cell carcinoma

Molecular and Clinical Oncology
Hirofumi OhmuraEishi Baba

Abstract

Inflammation is considered to be a prognostic factor for renal cell carcinoma (RCC). An inflammation-based prognostic score (modified Glasgow Prognostic Score; mGPS) is widely used for preoperative patients; however, little information is available regarding its prognostic value in patients with RCC treated with molecular-targeted drugs. A total of 32 advanced and recurrent RCC patients initially treated with molecular-targeted drugs from October, 2009 to August, 2015 were retrospectively investigated. Information on patient characteristics prior to treatment initiation and the clinical course were retrieved from clinical records. The correlation between survival and patient variables was analyzed. Survival was compared among patient groups according to the mGPS score. The median patient age was 66 years. The percentage of patients with an Eastern Cooperative Oncology Group performance status of 0 or 1 was 87.5, and 65.6% of the RCCs were clear cell carcinomas. A Memorial Sloan-Kettering Cancer Center index of good or intermediate was determined for 75% of the patients. Sunitinib, pazopanib or sorafenib was administered to 56, 22 and 13% of the cases, respectively. An mGPS score of 0, 1 and 2 was calculated for 66, 9 and 25% of...Continue Reading

References

Jun 1, 1996·British Journal of Cancer·H R ScottR Milroy
Aug 31, 2000·Nutrition and Cancer·P O'GormanC S McArdle
Jan 5, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert J MotzerMadhu Mazumdar
Oct 14, 2005·Kidney International·Wolfram J JabsChristian Doehn
Jan 12, 2007·The New England Journal of Medicine·Robert J MotzerRobert A Figlin
Jan 25, 2007·International Journal of Colorectal Disease·Donald C McMillanColin S McArdle
Oct 15, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Daniel Y C HengToni K Choueiri
Jan 27, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Cora N SternbergRobert E Hawkins
Oct 5, 2010·Japanese Journal of Clinical Oncology·Seiji NaitoMohamed Ibrahim Bin A Wahid
Feb 8, 2011·CA: a Cancer Journal for Clinicians·Ahmedin JemalDavid Forman
Mar 13, 2012·European Urology·Steven MacLennanUNKNOWN EAU Renal Cancer Guideline Panel
Jan 22, 2013·CA: a Cancer Journal for Clinicians·Rebecca SiegelAhmedin Jemal
Apr 17, 2013·International Journal of Oncology·Nandini D P K ManneEric Blough
Jun 19, 2013·The International Journal of Biochemistry & Cell Biology·Tadashi YoshidaPatrice Delafontaine
Jun 19, 2013·The International Journal of Biochemistry & Cell Biology·Bradley S GordonScot R Kimball
Aug 24, 2013·The New England Journal of Medicine·Robert J MotzerToni K Choueiri
Jul 23, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert J MotzerJennifer J Knox
Oct 8, 2014·Nature Reviews. Cancer·Josep M ArgilésFrancisco J López-Soriano
Apr 15, 2015·Asia-Pacific Journal of Clinical Oncology·Seyda GunduzHakan Bozcuk

❮ Previous
Next ❯

Citations

Nov 27, 2021·Pigment Cell & Melanoma Research·John DaviesJulia A Newton-Bishop

❮ Previous
Next ❯

Methods Mentioned

BETA
surgical resection

Software Mentioned

SPSS

Related Concepts

Related Feeds

Adenocarcinoma, Clear Cell

Clear Cell Adenocarcinoma is a tumor that arises in the female genital tract and is characterized by cells that appear clear under the microscope. Discover the latest research here.